XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Transactions - Additional Information (Details) - USD ($)
 2 Months Ended 12 Months Ended
Apr. 15, 2024
Oct. 27, 2023
Oct. 06, 2023
Jul. 19, 2023
Oct. 06, 2022
Sep. 07, 2021
Nov. 01, 2019
Jun. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Jul. 01, 2024
Feb. 07, 2023
Jun. 30, 2022
Equity Transactions                          
Interest expense                 $ 49,808        
Number of fully vested warrants granted to purchase shares of common stock                 1,144        
Non-cash compensation expense recognized                 $ 563 $ 44,000      
Common stock, $0.00001 par value; 150,000,000 shares authorized, 13,144,055 and 11,698,497 shares issued and outstanding at June 30, 2024 and 2023, respectively. (Note 8)               $ 131 $ 131 $ 117      
Common stock, par value (in dollars per share)               $ 0.00001 $ 0.00001 $ 0.00001      
Increased additional paid in capital                   $ 11,596      
Common shares issued as compensation and for services                 $ 178,940 157,822      
Employees                          
Equity Transactions                          
Stock-based compensation expense                 $ 2,340        
Shares granted                 1,786        
share-based payment arrangement, for consulting services                          
Equity Transactions                          
Vested shares                 101,542        
Share-based payment arrangement, nonemployee                          
Equity Transactions                          
Vested shares                 33,579        
Common shares issued as compensation and for services                 $ 131,600 45,000      
ATM Offering                          
Equity Transactions                          
Aggregate offering price $ 50,000,000                        
Issuance of shares               1,308,651          
Average price               $ 2.47 $ 2.47        
Net proceeds $ 3,120,000                        
Net proceeds from issuance of common stock                 $ 3,237,000        
After Redomiciliation                          
Equity Transactions                          
Number of shares issued on conversion of each share                       1  
Minimum                          
Equity Transactions                          
Exercise price of warrants                 $ 1.43        
Maximum                          
Equity Transactions                          
Exercise price of warrants                 $ 1.66        
Warrants                          
Equity Transactions                          
Number of fully vested warrants granted to purchase shares of common stock                 1,144        
Non-cash compensation expense recognized                 $ 1,012        
Warrants | Minimum                          
Equity Transactions                          
Exercise price (in dollars per share)               1.39 $ 1.39        
Warrants | Maximum                          
Equity Transactions                          
Exercise price (in dollars per share)               $ 3.40 $ 3.40        
Founder, Chairman and President                          
Equity Transactions                          
Employment agreement extension term (in years)     1 year                    
Founder, Chairman and President | Related party                          
Equity Transactions                          
Employment agreement extension term (in years)         1 year                
Preferred stock, par value (in dollars per share)                     $ 0.00001    
TheraCour Pharma Inc                          
Equity Transactions                          
Accounts payable                   $ 733,434      
TheraCour Pharma Inc | Related party                          
Equity Transactions                          
Number of shares upon principle of note convertible   331,859                      
Gain on extinguishment                 $ 49,808        
Issuance of shares             75,000            
TheraCour Pharma Inc | Related party | Unsecured promissory note                          
Equity Transactions                          
Interest rate per annum (as a percent)       12.00%                  
Director                          
Equity Transactions                          
Stock-based compensation expense                 $ 45,000        
Number of shares authorized               30,084 30,084        
Employee compensation                          
Equity Transactions                          
Stock-based compensation expense                 $ 4,822        
Number of shares authorized               3,572 3,572        
Consulting services                          
Equity Transactions                          
Stock-based compensation expense                 $ 108,000        
Number of shares authorized               72,668 72,668        
Common Stock                          
Equity Transactions                          
Issuance of shares                 1,308,651        
Common stock issued for consulting and legal services rendered (in shares)                 101,542 72,668      
Common stock issued for Directors fees (in shares)                 33,579 30,084      
Common Stock | Before Redomiciliation                          
Equity Transactions                          
Common stock, par value (in dollars per share)               $ 0.001 $ 0.001        
Common Stock | After Redomiciliation                          
Equity Transactions                          
Common stock, $0.00001 par value; 150,000,000 shares authorized, 13,144,055 and 11,698,497 shares issued and outstanding at June 30, 2024 and 2023, respectively. (Note 8)                   $ 116     $ 11,592
Common stock, par value (in dollars per share)               0.00001 0.00001        
Preferred Stock | Before Redomiciliation                          
Equity Transactions                          
Preferred stock par value                         $ 485
Preferred stock, par value (in dollars per share)               0.001 0.001        
Preferred Stock | After Redomiciliation                          
Equity Transactions                          
Number of shares issued on conversion of each share                       1  
Preferred stock par value                   5      
Preferred stock, par value (in dollars per share)               $ 0.00001 $ 0.00001        
Series A Preferred Stock | Founder, Chairman and President                          
Equity Transactions                          
Number of shares vest on quarterly installments     2,551                    
Shares granted     10,204                    
Series A Preferred Stock | Founder, Chairman and President | Related party                          
Equity Transactions                          
Number of shares vest on quarterly installments         2,551                
Non-cash compensation expense recognized                 $ 49,795        
Shares granted         10,204                
Series A Preferred Stock | TheraCour Pharma Inc                          
Equity Transactions                          
Number of shares upon principle of note convertible       331,859                  
Debt instrument, conversion stock, par value       $ 0.00001                  
Series A Preferred Stock | TheraCour Pharma Inc | Related party                          
Equity Transactions                          
Issuance of shares           50,000              
Series A Preferred Stock | Employee compensation                          
Equity Transactions                          
Stock-based compensation expense                 $ 10,747        
Number of shares authorized               2,888 2,888        
Series A Preferred Stock | Founder, Chairman and President                          
Equity Transactions                          
Non-cash compensation expense                 $ 32,498        
Series A convertible preferred stock                          
Equity Transactions                          
Preferred stock par value               $ 9 $ 9 $ 5      
Preferred stock, par value (in dollars per share)               $ 0.00001 $ 0.00001 $ 0.00001      
Number of shares authorized                   2,888      
Series A convertible preferred stock | Employee compensation                          
Equity Transactions                          
Stock-based compensation expense                   $ 12,000